Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's Lymphoma: a systematic review and economic evaluation

Research output: Contribution to journalArticle

Colleges, School and Institutes

Details

Original languageEnglish
Pages (from-to)1-85
Number of pages85
JournalHealth Technology Assessment
Volume6
Issue number3
Publication statusPublished - 1 Jan 2002